HomeCompareVINCW vs EPRT

VINCW vs EPRT: Dividend Comparison 2026

VINCW yields 124.22% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VINCW wins by $9.95M in total portfolio value
10 years
VINCW
VINCW
● Live price
124.22%
Share price
$1.61
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10.01M
Annual income
$3,875,023.48
Full VINCW calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — VINCW vs EPRT

📍 VINCW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVINCWEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VINCW + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VINCW pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VINCW
Annual income on $10K today (after 15% tax)
$10,559.01/yr
After 10yr DRIP, annual income (after tax)
$3,293,769.96/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, VINCW beats the other by $3,282,855.34/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VINCW + EPRT for your $10,000?

VINCW: 50%EPRT: 50%
100% EPRT50/50100% VINCW
Portfolio after 10yr
$5.04M
Annual income
$1,943,932.10/yr
Blended yield
38.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

VINCW
Analyst Ratings
1
Buy
Consensus: Buy
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VINCW buys
0
EPRT buys
0
No recent congressional trades found for VINCW or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVINCWEPRT
Forward yield124.22%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$10.01M$63.4K
Annual income after 10y$3,875,023.48$12,840.73
Total dividends collected$9.13M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: VINCW vs EPRT ($10,000, DRIP)

YearVINCW PortfolioVINCW Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$23,122$12,422.36$11,205$505.18+$11.9KVINCW
2$51,585$26,844.33$12,672$682.46+$38.9KVINCW
3$111,167$55,970.88$14,490$930.48+$96.7KVINCW
4$231,676$112,727.29$16,786$1,282.69+$214.9KVINCW
5$467,452$219,558.47$19,753$1,791.56+$447.7KVINCW
6$914,194$414,020.78$23,677$2,541.64+$890.5KVINCW
7$1,734,916$756,728.27$29,008$3,672.99+$1.71MVINCW
8$3,198,495$1,342,134.90$36,463$5,425.08+$3.16MVINCW
9$5,734,878$2,312,488.60$47,238$8,221.57+$5.69MVINCW
10$10,011,343$3,875,023.48$63,385$12,840.73+$9.95MVINCW

VINCW vs EPRT: Complete Analysis 2026

VINCWStock

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Full VINCW Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this VINCW vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VINCW vs SCHDVINCW vs JEPIVINCW vs OVINCW vs KOVINCW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.